Synmosa Biopharma Corporation (4114)
TWSE
29.90
-0.35 (-1.16%)
Real-time Data
01:00 AM
Day's Range
29.9030.25
52 wk Range
27.5535.14
Financial Statements - 4114 - Synmosa Biopharma Corporation
Revenue
6.18B▲ 11.5%
Net Income
618.42M▲ 31.9%Net Margin 10.0%
EBITDA
1.20B▲ 13.9%
Free Cash Flow
130.43M▼ 74.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 6.18B | 5.54B | 5.14B | 4.38B | 3.23B | 3.03B |
| Cost of Goods | 3.51B | 3.14B | 3.02B | 2.55B | 1.94B | 1.90B |
| Gross Profit | 2.67B | 2.40B | 2.11B | 1.82B | 1.28B | 1.13B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 777.93M | 739.08M | 620.33M | 455.02M | 185.20M | 119.51M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 799.64M | 659.06M | 601.55M | 725.01M | 153.88M | 497.64M |
| Income Tax | 181.21M | 190.18M | 196.38M | 106.12M | 37.81M | 23.04M |
| Net Income | 618.42M | 468.88M | 405.16M | 618.88M | 116.07M | 474.60M |
| EPS Basic | - | 1.473732 | 1.461511 | 2.042484 | 0.765507 | 1.810877 |
| EPS Diluted | - | 1.464691 | 1.461511 | 2.033406 | 0.757276 | 1.802645 |
| Basic Shares Outstanding | - | 464.80M | 406.75M | 391.60M | 398.33M | 352.79M |
| Diluted Shares Outstanding | - | 464.80M | 406.75M | 391.60M | 398.33M | 352.79M |
| Ebit | 861.70M | 717.16M | 668.81M | 784.59M | 205.85M | 550.46M |
| Ebitda | 1.20B | 1.05B | 1.01B | 1.10B | 509.73M | 678.35M |
| Net Income Continuous Operations | 799.64M | 659.06M | 601.55M | 725.01M | 153.88M | 497.64M |
| Minority Interests | 203.42M | 215.80M | 189.66M | 180.20M | 187.78M | 163.50M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
